A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients with borderline personality disorder.

Project: Research

Project Details

Effective start/end date1/12/2031/12/23


  • Psychiatry
  • Borderline Personality Disorder
  • Clinical trial